

CJASN[®]

Clinical Journal of the American Society of Nephrology

January 2022 • Vol. 17 • No 1

Patient Voice

1 An Honorable and Ongoing Fight: Protecting Organ Transplant Recipients against COVID-19 in the Age of Disinformation

Paul T. Conway

See related article on page 98.

Editorials

3 Protection against SARS-CoV-2 Variants with COVID-19 Vaccination in Kidney Transplant Recipients

Dominique Bertrand and Sophie Candon

See related article on page 98.

6 Waitlist Mortality for Second Kidney Transplants

Mohammad Kazem Fallahzadeh and Kelly A. Birdwell

See related article on page 90.

8 Accessibility of Nutrition Care for Kidney Disease Worldwide

Arpana Iyengar and Valerie A. Luyckx

See related article on page 38.

11 Trial Outcomes in Glomerular Diseases

Jonathan P. Troost

See related article on page 53.

14 Value-Based Care in Chronic Kidney Disease: Missing Albuminuria is a Missed Opportunity

Allison C. Reaves and Daniel E. Weiner

See related article on page 17.

Original Articles

Chronic Kidney Disease

17 Kidney Failure Risk Equation and Cost of Care in Patients with Chronic Kidney Disease

Bhanu Prasad, Meric Osman, Maryam Jafari, Lexis Gordon, Navdeep Tangri, Thomas W. Ferguson, Shan Jin, Joanne Kappel, and Diane Kozakewycz

See related editorial on page 14.

27 Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease

Insa M. Schmidt, Suraj Sarvode Mothi, Parker C. Wilson, Ragnar Palsson, Anand Srivastava, Ingrid F. Onul, Zoe A. Kibbelaar, Min Zhuo, Afolarin Amodu, Isaac E. Stillman, Helmut G. Rennke, Benjamin D. Humphreys, and Sushrut S. Waikar

38 Assessing Global Kidney Nutrition Care

Angela Yee-Moon Wang, Ikechi G. Okpechi, Feng Ye, Csaba P. Kovesdy, Giuliano Brunori, Jerrilynn D. Burrowes, Katrina Campbell, Sandrine Damster, Denis Fouque, Allon N. Friedman, Giacomo Garibotto, Fitsum Guebre-Egziabher, David Harris, Kunitoshi Iseki, Vivekanand Jha, Kailash Jindal, Kamyar Kalantar-Zadeh, Brandon Kistler, Joel D. Kopple, Martin Kuhlmann, Meaghan Lunney, Denise Mafra, Charu Malik, Linda W. Moore, S. Russ Price, Alison Steiber, Christoph Wanner, Pieter ter Wee, Adeera Levin, David W. Johnson, and Aminu K. Bello

See related editorial on page 8.

Glomerular and Tubulointerstitial Diseases

53 **A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology–Glomerular Disease (SONG-GD) Stakeholder Workshops**

Simon A. Carter, Liz Lightstone, Dan Cattran, Allison Tong, Arvind Bagga, Sean J. Barbour, Jonathan Barratt, John Boletis, Dawn J. Caster, Rosanna Coppo, Fernando C. Fervenza, Jürgen Floege, Michelle A. Hladunewich, Jonathan J. Hogan, A. Richard Kitching, Richard A. Lafayette, Ana Malvar, Jai Radhakrishnan, Brad H. Rovin, Nicole Scholes-Robertson, Hernán Trimarchi, Hong Zhang, Samaya Anumudu, Yeoungjee Cho, Talia Gutman, Emma O’Lone, Andrea K. Viecelli, Eric Au, Karolis Azukaitis, Amanda Baumgart, Amelie Bernier-Jean, Louese Dunn, Martin Howell, Angela Ju, Charlotte Logeman, Melissa Nataatmadja, Benedicte Sautenet, Ankit Sharma, and Jonathan C. Craig, on behalf of the SONG-GD Workshop Investigators
See related editorial on page 11.

65 **Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes**

Scott E. Wenderfer, Joyce C. Chang, Amy Goodwin Davies, Ingrid Y. Luna, Rebecca Scobell, Cora Sears, Bliss Magella, Mark Mitsnefes, Brian R. Stotter, Vikas R. Dharnidharka, Katherine D. Nowicki, Bradley P. Dixon, Megan Kelton, Joseph T. Flynn, Caroline Gluck, Mahmoud Kallash, William E. Smoyer, Andrea Knight, Sangeeta Sule, Hanieh Razzaghi, L. Charles Bailey, Susan L. Furth, Christopher B. Forrest, Michelle R. Denburg, and Meredith A. Atkinson

Hypertension

75 **Nocturnal Dipping and Left Ventricular Mass Index in the Chronic Kidney Disease in Children Cohort**

Christine Y. Bakhoum, Ronit Katz, Joshua A. Samuels, Tala Al-Rousan, Susan L. Furth, Joachim H. Ix, and Pranav S. Garimella

Nephrolithiasis

83 **Temporal Trends of Dietary Risk Factors after a Diagnosis of Kidney Stones**

Pietro Manuel Ferraro, Tamara Da Silva Cunha, Eric N. Taylor, and Gary C. Curhan

Transplantation

90 **Waiting Time for Second Kidney Transplantation and Mortality**

Alexander Kainz, Michael Kammer, Roman Reindl-Schwaighofer, Susanne Strohmaier, Vojtěch Petr, Ondrej Viklicky, Daniel Abramowicz, Marcel Naik, Gert Mayer, and Rainer Oberbauer
See related editorial on page 6.

98 **Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination**

Louise Benning, Christian Morath, Marie Bartenschlager, Christian Nusshag, Florian Kälble, Mirabel Buylaert, Matthias Schailer, Jörg Beimler, Katrin Klein, Julia Grenz, Paula Reichel, Asa Hidmark, Gerald Ponath, Maximilian Töllner, Marvin Reineke, Susanne Rieger, Burkhard Tönshoff, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, and Claudius Speer
See related Patient Voice on page 1 and editorial on page 3.

Research Letters

107 **Monitoring Daily Ultrafiltration in Automated Peritoneal Dialysis**

Fabian Eibensteiner, Krystell Oviedo Flores, Markus Unterwurzacher, Rebecca Herzog, Klaus Kratochwill, Seth L. Alper, Christoph Aufricht, Franz König, and Andreas Vychytil

111 **Cerebrovascular Response during Acute Exercise in Kidney Transplant Recipients**

Jaimie L. Ward, Madhuri Ramakrishnan, Andrew Jurgensen, Sandra Billinger, and Aditi Gupta

Kidney Transplantation Long-Term Management Challenges

114 **Post-Transplant Pregnancy and Contraception**

Christina L. Klein and Michelle A. Josephson

121 **Bone and Mineral Disease in Kidney Transplant Recipients**

Pascale Khairallah and Thomas L. Nickolas

Kidney Case Conference: How I Treat

131 **Optimizing Renin-Angiotensin System Inhibitor Use in CKD**

Tara I. Chang and Edgar V. Lerma

134 **Assessing Risk of Progression in ADPKD**

Craig E. Gordon, Dana C. Miskulin, and Ronald D. Perrone

Perspectives

137 The Kidney in Normal Aging: A Comparison with Chronic Kidney Disease

Aleksandar Denic, Richard J. Glassock, and Andrew D. Rule

140 Terlipressin: Hopes Fulfilled or Dashed?

Raimund H. Pichler, Erik R. Swenson, Peter J. Leary, and Cary H. Paine

Feature

143 Guidelines for Genetic Testing and Management of Alport Syndrome

Judy Savige, Beata S. Lipska-Zietkiewicz, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabet Ars, Agnieszka Bierzynska, Concetta Gangemi, Alessandra Renieri, Helen Storey, and Frances Flinter

Review

155 Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy

Constance C.F.M.J. Baaten, Jonas R. Schröer, Jürgen Floege, Nikolaus Marx, Joachim Jankowski, Martin Berger, and Heidi Noels

On the Cover

What is the Diagnosis?

A 71-year-old male presented for evaluation of heart failure; the patient had acute on chronic kidney injury (serum creatinine, 2.1 mg/dl) and nephrotic-range proteinuria. Serum immunofixation demonstrated monoclonal IgM lambda (451 mg/dl) and IgM kappa (195 mg/dl), kappa-to-lambda ratio: 0.43; β_2 microglobulin: 7.42 mg/L. Multiple bands with restricted mobility were evident on urine immunofixation.

Image Description:

Kidney biopsy demonstrated diffuse nodular mesangial expansion with Congo red positive birefringent amyloid deposits (top, inset; bar 40 μ m) and fibrils on electron microscopy (bottom, inset; bar 40 nm). Immunofluorescence showed 3+ smudgy glomerular IgM (left), 1+ smudgy kappa (middle), and 3+ smudgy lambda (right) staining. IgM and lambda were stronger than kappa. Lambda alone showed interstitial staining (200x).

Teaching Points:

Immunofluorescence staining raised the possibility of AHL amyloid (heavy-and-light-chain amyloid). However, with multiple monoclonal proteins in the serum and urine and a mixed picture on immunofluorescence, mass spectrometry-based confirmation was sought. It revealed only light chain (AL-lambda) amyloid, and not the rare AH (immunoglobulin-heavy-chain amyloid) or AHL amyloid. The IgM heavy chain was not forming amyloid fibrils. Although this may not alter clinical management, prognostic differences have been shown with this rare AH/AHL entity, highlighting the importance for accurate recognition (1). An important clue was the absence of IgM and kappa in the interstitium. Subsequent bone marrow biopsy revealed lymphoplasmacytic lymphoma, the most commonly identified condition associated with IgM-associated AL amyloidosis, with MYD88^{L265P} and CXCR4^{WHIM/FS} mutations. As therapeutic intervention, the addition of daratumumab to standard therapy—bortezomib, cyclophosphamide, and dexamethasone—was utilized based on the ANDROMEDA trial results (2).

References:

1. Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Dispenzieri A, Buadi FK, Vrana JA, Theis JD, Dogan A, Leung N: The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. *Kidney Int* 83: 463–470, 2013
2. Kastiris E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sancharawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim J-S, Crusoe E, Ahmadi T, Tran NP, Qin X, Vasey SY, Tromp B, Schechter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators: Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. *New England J Med* 385: 46–58, 2021 (Image and text provided by Yannis Hadjiyannis, Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; Anne T. Taylor, Department of Renal Pathology, Wexner Medical Center, The Ohio State University, Columbus, Columbus, Ohio; Naresh Bumma, Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; Aijaz Gundroo, Division of Nephrology, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio; Francesca Cottini, Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; Anjali A. Satoskar, Department of Renal Pathology, Wexner Medical Center, The Ohio State University, Columbus, Columbus, Ohio)